| Year |
Citation |
Score |
| 2019 |
Cai B, Said Q, Li X, Li FY, Arcona S. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag. Journal of Medical Economics. 1. PMID 31686551 DOI: 10.1080/13696998.2019.1688820 |
0.349 |
|
| 2019 |
Huynh L, Cai B, Cheng M, Lax A, Lejeune D, Duh MS, Kim MK. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. Pancreas. PMID 31593022 DOI: 10.1097/Mpa.0000000000001403 |
0.405 |
|
| 2019 |
Cai B, Said Q, Li X, Li FY, Arcona S. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US. Journal of Medical Economics. 1. PMID 31296074 DOI: 10.1080/13696998.2019.1643354 |
0.339 |
|
| 2019 |
Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. Bmc Cancer. 19: 274. PMID 30922252 DOI: 10.1186/S12885-019-5459-X |
0.31 |
|
| 2019 |
Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. The Oncologist. PMID 30610008 DOI: 10.1634/Theoncologist.2018-0520 |
0.344 |
|
| 2019 |
Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. The Oncologist. PMID 30606883 DOI: 10.1634/Theoncologist.2018-0519 |
0.344 |
|
| 2019 |
Huynh L, Cai B, Sharperson C, Lejeune D, Duh MS, Kim MK. Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET). Journal of Clinical Oncology. 37: 105-105. DOI: 10.1200/Jco.2019.37.4_Suppl.105 |
0.362 |
|
| 2018 |
Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine. 97: e13390. PMID 30461659 DOI: 10.1097/Md.0000000000013390 |
0.329 |
|
| 2018 |
Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. Bmc Pulmonary Medicine. 18: 135. PMID 30103725 DOI: 10.1186/S12890-018-0678-5 |
0.321 |
|
| 2018 |
Broder MS, Cai B, Chang E, Yan T, Benson AB. Treatment adherence, healthcare resource utilization and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA. Current Medical Research and Opinion. 1-14. PMID 30047289 DOI: 10.1080/03007995.2018.1505277 |
0.369 |
|
| 2018 |
Broder MS, Cai B, Chang E, Yan T, Benson AB. First-line systemic treatment adherence, healthcare resource utilization and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. Journal of Medical Economics. 1-17. PMID 29741466 DOI: 10.1080/13696998.2018.1474748 |
0.378 |
|
| 2018 |
Broder MS, Cai B, Chang E, Neary MP, Papoyan E, Benson Iii AB. Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis. Oncology. PMID 29510379 DOI: 10.1159/000486282 |
0.337 |
|
| 2018 |
Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary M, Bergsland EK. Real-world analysis of treatment patterns and persistence of octreotide LAR and other agents in patients with advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter study. Journal of Clinical Oncology. 36: 424-424. DOI: 10.1200/Jco.2018.36.4_Suppl.424 |
0.331 |
|
| 2018 |
Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak R, Narkhede S, Duh MS, Neary M, Cella D. Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys. Journal of Clinical Oncology. 36: 400-400. DOI: 10.1200/Jco.2018.36.4_Suppl.400 |
0.306 |
|
| 2018 |
Cai B, Broder M, Chang E, Yan JT, Benson AB. Treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs). Journal of Clinical Oncology. 36: 337-337. DOI: 10.1200/Jco.2018.36.4_Suppl.337 |
0.383 |
|
| 2017 |
Benson Iii AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World Journal of Gastroenterology. 23: 6128-6136. PMID 28970728 DOI: 10.3748/Wjg.V23.I33.6128 |
0.329 |
|
| 2017 |
Broder MS, Cai B, Chang E, Neary MP. EPIDEMIOLOGY OF GASTROINTESTINAL NEUROENDOCRINE TUMORS IN A US COMMERCIALLY INSURED POPULATION. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. PMID 28704096 DOI: 10.4158/Ep171879.Or |
0.314 |
|
| 2017 |
Broder MS, Chang E, Cai B, Neary MP, Papoyan E, Benson AB. Treatment Patterns of Lung Neuroendocrine Tumors (NETs). International Journal of Radiation Oncology, Biology, Physics. 98: 242. PMID 28587024 DOI: 10.1016/J.Ijrobp.2017.01.177 |
0.324 |
|
| 2017 |
Broder MS, Chang E, Cai B, Neary M, Papoyan E, Benson AB. Treatment patterns of gastrointestinal neuroendocrine tumors (NET). Journal of Clinical Oncology. 35: 387-387. DOI: 10.1200/Jco.2017.35.4_Suppl.387 |
0.369 |
|
| 2017 |
Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak R, Duh MS, Vekeman F, Neary M, Cella D. Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E15693 |
0.301 |
|
| 2017 |
Cai B, Broder M, Chang E, Yan T, Metz DC. Predictive factors of carcinoid syndrome among patients with gastrointestinal neuroendocrine tumors (GI NETs). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E15690 |
0.32 |
|
| 2016 |
Rose DB, Nellesen D, Neary MP, Cai B. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Journal of Medical Economics. 1-19. PMID 27981858 DOI: 10.1080/13696998.2016.1273228 |
0.331 |
|
| 2016 |
Cai B, Broder MS, Chang E, Burk C, Grzegorzewski KJ, Neary MP. PS01.23: Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S282-S283. PMID 27969490 DOI: 10.1016/J.Jtho.2016.09.058 |
0.306 |
|
| 2016 |
Cai B, Broder MS, Chang E, Burk C, Grzegorzewski K, Neary M. Epidemiology of neuroendocrine tumors (NET) of the lung in the US: Analysis of 2 large insurance claims databases. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E13071 |
0.322 |
|
| 2013 |
Cai B, Nickman NA, Gaffney DK. The cost-effectiveness of external beam radiation therapy in bone metastases. Current Opinion in Supportive and Palliative Care. 7: 278-83. PMID 23912387 DOI: 10.1097/Spc.0B013E328362E8E3 |
0.302 |
|
| 2011 |
Cai B, Cameron TA, Gerdes GR. Distal order effects in stated preference surveys Ecological Economics. 70: 1101-1108. DOI: 10.1016/J.Ecolecon.2010.12.018 |
0.555 |
|
| 2010 |
Cai B, Cameron TA, Gerdes GR. Distributional preferences and the incidence of costs and benefits in climate change policy Environmental and Resource Economics. 46: 429-458. DOI: 10.1007/S10640-010-9348-7 |
0.563 |
|
| Show low-probability matches. |